Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam's Overshadowed Givosiran Comes Into The Phase III Light

While attention has been focused on other products, Alnylam is set to take another RNAi product candidate – givosiran – into pivotal testing following positive early data in acute hepatic porphyria.

Clinical Trials Companies Metabolic Disorders

Better Incentives Needed For Worsening Fungal Infection Threat

The increasing threat of treatment-resistant Candida auris fungal infections suggests the need for greater development incentives, CEOs of three antifungal drug developers told the recent BIO annual meeting.

Infectious Diseases Business Strategies Regulation

What Now For Lonely Stada? Bain & Civen Takeover Bid Collapses

In a surprising twist, Stada investors have not rallied behind a €5.3bn takeover bid from equity groups Bain and Civen; analysts are baffled as to why the deal didn’t win enough support and what Stada's shareholders are hoping for now.

Generic Drugs Deals Business Strategies

Mehta Analysis: Shaming Biopharma Managers

Shame has historically been used as an effective tool in bringing about a change in pricing policy within an industry. But could it be wielded against the pharma industry today? Viren Mehta, founding partner of Mehta Partners, LLC, considers.

Pricing Debate United States Business Strategies
Advertisement


 Recent Tweets from Scrip


Commercial Explore this Topic

Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation

As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.

Deals Companies Business Strategies

ImCheck Therapeutics Pursues Immuno-Oncology Antibodies

Emerging Company Profile: The new anticancer antibody developer ImCheck Therapeutics has set up in Marseille, France, a location that is becoming increasingly attractive to biotech start-ups that could rival more established areas in coming years.

ImmunoOncology StartUps and SMEs France

Latest From Commercial

Biological E Taps Takeda Tech For Affordable Combo Vaccines

Takeda is to transfer selected vaccine technologies to an Indian manufacturer to enable the production of affordable combination vaccines for lower income countries, although likely volumes and prices remain unclear for now.

Vaccines Manufacturing

Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC

Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.

Deals M & A

Bio Boost For Benelux As BioGeneration Ventures Beats Fund Target

Dutch life sciences venture capital firm BioGeneration Ventures has exceeded the €50m target in a third closing of its BGV III fund, raising €66m. It intends to focus its investments on firms in the Netherlands, Belgium, Luxembourg and Germany, and expects to secure further funds, reaching the maximum fund size of €75m by the end of 2017.

Financing StartUps and SMEs

Profile: VC Forbion's Slootweg Sees Bigger And Better European Funds

Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.

Leadership Financing

Podcast: Scaling Up Your Business

BIO International 2017 discussion: growing a biotech business. Informa's global content editor Mike Ward discusses how to scale up your SME and access international markets with experts in the field. This content was produced by Scrip alongside a sponsored project with MSP, a provider of specialized science campuses in Manchester and Cheshire, UK.

Business Strategies StartUps and SMEs

Obituary: Lupin’s founder Desh Bandhu Gupta And His People Mantra

Lupin’s founder and chairman, Desh Bandhu Gupta, who died aged 79 on June 26, was known to give employees significant autonomy at the workplace, with some saying that people were the crux of his company-building mantra.

India Commercial

Policy & Regulation Explore this Topic

Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market

Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.

Approvals Launches Cardiovascular

Open Innovation: The Fast-Track To Global Pharma Power For Korea?

Although South Korea has a good clinical trial infrastructure, workforce, and novel drug development technology, it still lacks the power to lead the development of new drugs across the finish line. The country needs to create an environment that can attract multinationals to co-research and co-develop drugs with domestic pharma firms under open innovation programs if Korea-originated blockbusters are ever to emerge, experts told a recent forum in Seoul.

South Korea Policy & Regulation

Generic Drug Market Has Gaps, FDA Tells Firms In Solicitation For ANDAs

US agency unveils plans to speed reviews of generic applications in areas with limited competition and offers a list of potential targets, but threat to brands may be limited.

Pricing Debate FDA

This Means War: Identical Labels Recommended For Gilead, AbbVie's HCV Drugs In Europe

AbbVie and Gilead have won positive recommendations in Europe and matching eight-week dosing labels for their latest hepatitis C combination therapies, Maviret and Vosevi – now it's all about the price.

Approvals Infectious Diseases

Research & Development Explore this Topic

Pulmotect Seeks Quick-To-Market Path For Rapid-Acting Respiratory Drug

Selected by NIH and NSF for the Innovation Zone at BIO 2017, the Houston biotech's synthetic broad-spectrum drug has shown activity in animal models against every pathogen tested. Pulmotect hopes PUL-042 can prevent exacerbations in COPD patients who develop upper respiratory infections.

Respiratory Infectious Diseases Business Strategies

Latest From Research & Development

'Affordable' Russian Rituximab Biosimilar On Course In India

Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.

Biosimilars Approvals

ConSynance Differentiates NASH Asset To Charm China

Dr. Shuang Liu, president and co-founder of ConSynance Therapeutics, talks with Scrip’s Brian Yang about the US-based startup's plans to develop and commercialize in China its assets for indications including NASH.

China Research & Development

Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?

Merck & Co has triumphed against the odds announcing positive top-line results from the cardiovascular outcomes trial of its CETP inhibitor anacetrapib. But questions remain about the level of benefit and the regulatory prospects.

Clinical Trials Cardiovascular
UsernamePublicRestriction

Register

Advertisement